

Beyond Winter Colds: Why Respiratory Vaccination Matters for Healthy Ageing

THE BURDEN:
As Populations Age, Respiratory Risks Rise

AGEING POPULATION

Globally, adults over 60 already outnumber children under 5, and will represent almost 1/4th of the population by 2050 (over 2 billion people)[1]

CHRONIC CONDITIONS

With age comes more prominent chronic medical conditions, inc. CVDs as leading global cause of death[2]

RESPIRATORY INFECTIONS

Age and chronic diseases amplify the impact of respiratory infections- and vice versa

> *"For older and other at-risk adults, a respiratory infection goes far beyond the lungs - exacerbating chronic conditions and triggering life-altering outcomes: hospitalization, pneumonia, heart attacks, strokes, and functional or cognitive decline[3,4,5]"*

Burden of Respiratory Infections in *Older and Other At-Risk Adults*

Influenza


24% increase in heart failure hospitalization[6]

1 in 5 older adults lose independence after flu hospitalization[7]

Pertussis

Diagnosed ***~3.2×*** more with asthma

Diagnosed ***~1.9×*** more with COPD[10]



COVID-19

93% of deaths in Europe occurred in people aged 65+[8]

RSV/HMPV

~40% of older adults hospitalized with RSV/HMPV develop complications (pneumonia, cardiovascular)[9]

WHY PREVENTION MATTERS
Vaccination is a Pillar of Healthy Ageing and a Societal, Economic and Clinical Imperative

Childhood immunization transformed public health. Adult immunization holds the same promise

Up to ***19×*** ROI from adult immunization[11] **Vs** vs. ***2-3×*** for smoking cessation[12]

> *"Preventing respiratory infections goes far beyond avoiding winter colds. It means reducing hospitalizations, preventing cardiovascular events, and helping older adults preserve their independence"*

Example: Influenza Vaccination

Preventable Hospitalizations

Up to **65,600** hospitalizations preventable every year in the EU[13]. 180,000 (95% CI: 140,000-310,000) hospitalizations were prevented in the US in flu season of 2024-2025[14]

Reduction in Cardiovascular Events

36% reduction in major cardiovascular events with flu vaccination in at-risk people[13]

Tailored Vaccines

Designed for older adults recommended preferentially in a growing number of countries. Recommended for adults >65 years in the US

COPD = Chronic Obstructive Pulmonary Disease; **CVD** = Cardiovascular Disease; **EU** = European Union; **HMPV** = Human Metapneumovirus; **ROI** = Return on Investment; **RSV** = Respiratory Syncytial Virus.

sanofi

©Sanofi 2026 - All rights reserved

MAT-US-2609768-v1.0-P-Approved 10/2026

OUR SANOFI COMMITMENT

Shaping the Future of Respiratory Care and Prevention for Healthy Ageing

Experience

Decades of experience across the full spectrum of respiratory health — from immunization to treatments for chronic conditions

Innovations

Innovation for prevention across the lifespan via multiple technologies: recombinant protein, mRNA, monoclonal antibodies, and other innovative immunization designs

Our Adult Vaccine Portfolio and Pipeline

- Influenza
- COVID-19
- Pertussis
- Meningococcal disease
- Combination vaccines: Flu/COVID and RSV+HMPV
- Hep B
- Shingles

€1.4 billion+ invested in vaccine R&D last year — majority driven by adult vaccines

Sanofi is committed to helping adults remain healthy, independent and thriving at every age

CALL TO ACTION

Now Is the Time: Prevention Saves Lives and Hundreds of Millions in Healthcare Costs

SAVE LIVES
Prevent severe illness. Reduce hospitalizations

INDEPENDENCE
Support healthy ageing. Preserve quality of life

HEALTH SYSTEM RESILIENCE
Reduce healthcare burden
Improve sustainability

The Question Isn't Whether We Can Act. It's Whether We Can Afford Not To

Every stakeholder has a critical role to play in making healthy ageing through immunization a reality

POLICYMAKERS & PAYERS
To establish older adults' immunization as a key priority in prevention policies & budget, with clear ownership, measurement, and targets

HCPS & SCIENTIFIC SOCIETIES
To recognize the broader value of older adults' immunization in preventing acute infections and beyond, including chronic conditions, and consistently recommend vaccination to support healthy ageing

OLDER ADULTS
To view immunization as a core pillar of healthy ageing, with strong familiarity with and access to recommended vaccines

Each year of inaction = measurable cost on lives, independence and health system resilience

REFERENCES

1. World Health Organization. Ageing and Health. WHO Factsheet. 2025. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health
2. World Health Organization. Cardiovascular Diseases (CVDs). WHO Factsheet. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
3. Vetrano DL, Triolo F, Maggi S, Malley R, Jackson TA, Poscia A, et al. Fostering healthy aging: The interdependency of infections, immunity and frailty. Ageing Res Rev. 2021;69(101351):101351. http://dx.doi.org/10.1016/j.arr.2021.101351
4. Global Coalition on Aging, Vaccine-Prevent able Respiratory Disease, Life Course Immunization, And Chronic Disease Management: The Healthy Aging Difference. Globalcoalitiononaging.com. 2025. https://globalcoalitiononaging.com/wp-content/uploads/2025/04/GCOA_LCI_NCD_Report_FINAL.pdf
5. From innovation to access: Pharmaceutical industry priorities ahead of the 4th UN High-Level Meeting on NCDs and Mental Health. IFPMA. 2025. Available from: https://www.ifpma.org/publications/from-innovation-to-access-pharmaceutical-industry-priorities-ahead-of-the-4th-un-high-level-meeting-on-ncds-and-mental-health/
6. Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, et al. Association of influenza-like illness activity with hospitalizations for heart failure: The Atherosclerosis Risk in communities study: JAMA Cardiol. 2019;4(4):363–9. http://dx.doi.org/10.1001/jamacardio.2019.0549
7. Andrew MK, MacDonald S, Godin J, McElhaney JE, LeBlanc J, Hatchette TF, et al. Persistent functional decline following hospitalization with influenza or acute respiratory illness. J Am Geriatr Soc. 2021;69(3):696–703. http://dx.doi.org/10.1111/jgs.16950
8. World Health Organization. WHO COVID-19 Detailed Surveillance Data Dashboard. https://app.powerbi.com/view?r=eyJrIjoiY2UyNmQ0MWQtYjdiZC00MmIyLWI5YmYtZmRiZWJkZDcyMDMwIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9
9. Falsey AR, Walsh EE, House S, Vandenijck Y, Ren X, Keim S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults-A global study during the 2017-2019 epidemic seasons (hospitalized acute respiratory tract infection [HARTI] study). Open Forum Infect Dis. 2021;8(11):ofab491. http://dx.doi.org/10.1093/ofid/ofab491
10. Buck PO, Meyers JL, Gordon L-D, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109–21. http://dx.doi.org/10.1017/S0950268817000887
11. OHE Contract Research. Socio-Economic Value of Adult Immunisation Programmes. Ohe.org. 2024. https://www.ohe.org/publications/the-socio-economic-value-of-adult-immunisation-programmes/
12. Baker CL, Ding Y, Ferrufino CP, Kowal S, Tan J, Subedi P. A cost-benefit analysis of smoking cessation prescription coverage from a US payer perspective. Clinicoecon Outcomes Res. 2018;10:359–70. http://dx.doi.org/10.2147/CEOR.S165576
13. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis: A meta-analysis. JAMA. 2013;310(16):1711–20. http://dx.doi.org/10.1001/jama.2013.279206
14. Centers for Disease Control and Prevention. Flu burden estimates. Available from https://www.cdc.gov/flu-burden/php/data-vis-vac/index.html

HCP = Healthcare Professional; **Hep B** = Hepatitis B; **HMPV** = Human Metapneumovirus; **mRNA** = Messenger Ribonucleic Acid; **R&D** = Research and Development; **RSV** = Respiratory Syncytial Virus

sanofi

©Sanofi 2026 - All rights reserved

MAT-US-2609768-v1.0-P-Approved 10/2026